Premium
Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes
Author(s) -
Zhuang Luning,
Chen Jianmeng,
Yu Jingyu,
Marathe Anshu,
Sahajwalla Chandra,
Borigini Mark,
Maynard Janet,
Burckart Gilbert J.,
Wang Yaning
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1302
Subject(s) - canakinumab , medicine , familial mediterranean fever , pediatrics , arthritis , macrophage activation syndrome , anakinra , dermatology , disease
Periodic fever syndromes are a group of rare diseases with a highly variable onset, yet limited treatment options are available for children at an early age. Canakinumab has been approved to treat patients with cryopyrin‐associated periodic syndrome, a periodic fever syndrome, and systemic juvenile systemic arthritis, with age cutoffs of 4 years and 2 years, respectively. In 2016, the US Food and Drug Administration ( FDA ) approved canakinumab, without an age restriction, for the treatment of three conditions of periodic fever syndromes, including familial Mediterranean fever, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, and tumor necrosis factor receptor‐associated periodic syndrome. This review discusses the pharmacokinetic ( PK ), efficacy, safety, and exposure‐response relationship of canakinumab and provides the rationale for dosage recommendation in children younger than 2 years of age with the three conditions of periodic fever syndromes. The approval of canakinumab for these pediatric patients addresses a critical unmet medical need.